Absolute lymphocyte count and lymphocyte subset profiles during long-term treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Fox, Robert J. [1 ]
Chan, Andrew [2 ]
Gold, Ralf [2 ]
Phillips, J. Theodore [3 ]
Selmaj, Krzysztof [4 ]
Zhang, Ray [5 ]
Chang, Ih [5 ]
Prada, Claudia [5 ]
Ray, Soma [5 ]
Mehta, Devangi [5 ]
Taylor, Catherine [5 ]
Marantz, Jing [5 ]
机构：
[1] Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Ruhr Univ, St Josef Hosp, Bochum, Germany
[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[4] Med Univ Lodz, Lodz, Poland
[5] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
107
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [41] Safety of Delayed-release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis Patients from ENDORSE: Seven-Year Interim Results
    Pozzilli, Carlo
    Phillips, J. Theodore
    Fox, Robert J.
    Prada, Claudia
    Yang, Lili
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [42] Delayed-release dimethyl fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple sclerosis
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Bar-Or, A.
    Fox, R. J.
    Chen, C.
    Miller, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 498 - 499
  • [43] MRI Outcomes at Seven Years in Relapsing-Remitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE
    Arnold, Douglas L.
    Fox, Robert J.
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Yousry, Tarek
    MacManus, David
    Yang, Lili
    Riester, Katherine
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [44] PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL
    Desai, U.
    Huang, M.
    Kirson, N. Y.
    King, S.
    Hellstern, M.
    Schonfeld, S.
    Birnbaum, H. G.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (05) : A195 - A195
  • [45] COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
    Silva Miguel, L.
    de Sa, J.
    Pinheiro, B.
    Acosta, C.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [46] Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis
    Sattarnezhad, Neda
    Healy, Brian C.
    Baharnoori, Moogeh
    Diaz-Cruz, Camilo
    Stankiewicz, James
    Weiner, Howard L.
    Chitnis, Tanuja
    NEUROLOGY, 2017, 88
  • [47] Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis
    Saijo, Naoya
    Abe, Yu
    Oikawa, Yoshitsugu
    Okubo, Yukimune
    Endo, Wakaba
    Numata-Uematsu, Yurika
    Takahashi, Toshiyuki
    Uematsu, Mitsugu
    BRAIN & DEVELOPMENT, 2022, 44 (05): : 353 - 356
  • [48] Absolute Lymphocyte Counts Are Not a Biomarker of Clinical Response in Patients Treated With Delayed-Release Dimethyl Fumarate
    Longbrake, Erin
    Mao-Draayer, Yang
    Matthews, Paul M.
    Foley, John
    Zielinski, Tomasz
    Chen, Chongshu
    Mokliatchouk, Oksana
    Parks, Becky
    Sharma, Ankur
    Xing, Diana
    Kapadia, Shivani
    Bame, Eris
    NEUROLOGY, 2020, 94 (15)
  • [49] Lymphocyte subpopulation in patients with relapsing-remitting multiple sclerosis and SPMS
    Belniak, E.
    Bojarska-Junak, A.
    Mitosek-Szewczyk, K.
    Bartosik-Psujek, H.
    Stehmasiak, Z.
    Rolinski, J.
    MULTIPLE SCLEROSIS, 2007, 13 : S43 - S43
  • [50] Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
    Fernandez, Oscar
    Giovannoni, Gavin
    Fox, Robert J.
    Gold, Ralf
    Phillips, J. Theodore
    Potts, James
    Okwuokenye, Macaulay
    Marantz, Jing L.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : 1671 - 1679
12345